Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells

Current Opinion in Investigational Drugs

Volumn 9, Issue 11, 2008, Pages 1216-1227

  Gatto, B ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; B LYMPHOCYTE; BLOOD DISEASE; BLOOD PRESSURE; BLOOD TOXICITY; BODY TEMPERATURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; FATIGUE; HEART RATE; HUMAN; IMMUNOMODULATION; IMMUNOTOXICITY; INFLUENZA VIRUS A H3N2; INJECTION SITE CONTUSION; INJECTION SITE REACTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYELOMA; NAUSEA; NEPHROTOXICITY; NERVOUS SYSTEM INFLAMMATION; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIC NEURITIS; PATENT; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54949118810     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. 272609 New drug for non-Hodgkin's lymphoma available now. Genentech Inc PRESS RELEASE 1997 December 16
2. 419726 TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M et al NATURE 2000 404 6781 995-999 • Provides the first demonstration of therapeutic feasibility of TACI:Fc decoy receptors as BLyS antagonists and describes the implications for the progression of SLE.
3. 419729 Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL J EXP MED 1999 190 11 1697-1710
4. 420939 ZymoGenetics teams with Serono on autoimmune disease therapeutics. ZymoGenetics Inc PRES RELEASE 2001 September 04
5. 518602 HGS begins phase II trial of LymphoStat-B in RA Human Genome Sciences Inc PRESS RELEASE 2004 January 08
6. 556849 ZymoGenetics announces start of TACI-Ig clinical study in rheumatoid arthritis. ZymoGenetics Inc PRESS RELEASE 2004 August 04
7. 566628 Excellent third quarter with strong EPS growth of 54.2%. Serono SA PRESS RELEASE 2004 October 26
8. 641122 Phase I/II study of TACI-Ig to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma or active previously-treated Waldenström's macroglobulinemia. Rossi JF, Borghini-Fuhrer I, Moreaux J, Requirand G, Bouseida S, Picard M, Ythier A, Sievers E, Klein B BLOOD 2005 106 11 Abs 2566
9. 664534 Roche showed continued strong sales growth in the first quarter 2006 - Sales up by 15%. Roche Holding AG PRESS RELEASE 2006 April 26
10. 750591 Phase 1 clinical study of atacicept in patients with relapsed and refractory B-cell lymphoma. Ansell S, Witzig TE, Novak A, Inwards DJ, Porrata L, Ythier A, Ferrande L, Nestorov I, DeVries T, Sievers E BLOOD 2006 108 11 Abs 2722
11. 750858 A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenströms macroglobulinemia (WM). Rossi J-F, Moreaux J, Rose M, Picard M, Ythier A, Rossier C, Sievers E, Klein B BLOOD 2006 108 11 Abs 3578
12. 752552 ZymoGenetics and Serono start atacicept phase II RA trial. ZymoGenetics Inc PRESS RELEASE 2006 December 20
13. 764508 NCT00410384: A study of belimumab, a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE). CLINICALTRIALS.GOV 2007 January 18
14. 797172 A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL). Kofler DM, Elter T, Gianella-Borradori A, Busby S, Wendtner CM, Hallek M AM SOC CLIN ONCOL 2007 43 Abs 3029
15. 820518 Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M EUR J CLIN PHARMACOL 2007 63 7 647-656
16. 836866 A phase Ib study to investigate atacicept (TACI-Ig) in patients with rheumatoid arthritis. Tak PP, Thurlings RM, Dimic A, Mircetic V, Rischmueller M, Nasanov E, Shmidt E, Emery P, Rossier C, Nesterov I, Hill J, Munafo A ANN RHEUM DIS 2007 66 Suppl 1 Abs 014
17. 836868 Trial of atacicept in patients with systemic lupus erythematosus (SLE). Dall'Era M, Chakravarty E, Genovese M, Wallace D, Kavanaugh A, Kalunian K, Dhar P, Pena-Rossi C, Wofsy D, Serono ZAS ARTHRITIS RHEUM 2006 54 12 4042-4043
18. 836869 B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM BLOOD 2006 107 7 2882-2888
19. 836870 Influenza virus host response of C57Bl/6 mice treated with TACI-Ig. Roque R, Ponce R, Burleson F, Cabrit M, Broly H, Rogge M IMMUNOPHARMACOL IMMUNOTOXICOL 2006 28 1 13-32
20. 836872 TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S et al IMMUNITY 2001 15 2 289-302 •• The first demonstration of therapeutic feasibility of TACI:Fc decoy receptors in the progression of RA is discussed.
21. 836896 Corticosterone inhibits the lipid-mobilizing effects of oleoyl-estrone in adrenalectomized rats. del Mar Grasa M, Serrano M, Fernandez-Lopez JA, Alemany M ENDOCRINOLOGY 2007 148 8 4056-4063
22. 860795 ZymoGenetics and Merck Serono initiate phase 2/3 clinical trial of atacicept in lupus nephritis. ZymoGenetics Inc PRESS RELEASE 2007 December 13
23. 861035 Merck Serono announces initiation of phase II/III clinical trial of atacicept in lupus nephritis. Merck Serono SA PRESS RELEASE 2007 December 13
24. 872769 NCT00282347: A study to evaluate the efficacy and safety of rituximab in subjects with ISN/RPS class III or IV lupus nephritis (LUNAR). CLINICALTRIALS.GOV 2008 January 31
25. 872782 NCT00137969: A study to evaluate the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (EXPLORER). CLINICALTRIALS.GOV 2008 January 01
26. 878078 Business review and results presentation full year 2007. Merck KgaA COMPANY PRESENTATION 2008 February 18
27. 883681 Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D, Novak AJ CLIN CANCER RES 2008 14 4 1105-1110
28. 901158 Merck Serono and ZymoGenetics initiate atacicept phase 2 clinical trial in relapsing multiple sclerosis. ZymoGenetics Inc PRESS RELEASE 2008 April 30
29. 903328 ZymoGenetics reports first quarter 2008 financial results. ZymoGenetics Inc PRESS RELEASE 2008 May 06
30. 913800 ZymoGenetics and Merck Serono initiate second phase 2/3 clinical study of atacicept in lupus. ZymoGenetics Inc PRESS RELEASE 2008 June 05
31. 914028 Merck Serono announces initiation of second phase II/III clinical study of atacicept in lupus. Merck Serono SA PRESS RELEASE 2008 June 05
32. 919166 Non-clinical safety, pharmacokinetics and pharmacodynamics of atacicept. Carbonatto M, Yu P, Bertolino M, Vigna E, Steidler S, Fava L, Daghero C, Roattino B, Onidi M, Ardizzone M, Ponce RA et al TOXICOL SCI 2008 June 02
33. 921188 TACI-Ig in patients with rheumatoid arthritis (RA): An exploratory, multi-centre, double-blind, placebo-controlled, dose-escalating, single and repeat dose phase IB study. Munafo A, Rossier C, Peter N, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasanov E, Shmidt E et al ANN RHEUM DIS 2007 65 2 Abs P0178
34. 921189 Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. Nestorov I, Munafo A, Papasouliotis O, Visich J J CLIN PHARMACOL 2008 48 4 406-417
35. 921199 Pharmacokinetics and biological activity of atacicept after intravenous and subcutaneous administration to SLE patients. Nestorov I, Munafo A, Papasouliotis O, Rogge M, Dall'Era M, Wofsy D, Chakravarty E, Genovese M, Weisman M, Kavanaugh A, Wallace D et al ANN RHEUM DIS 2007 66 Suppl 2 57
36. 921200 Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D ARTHRITIS RHEUM 2008 56 12 4142-4150
37. 921202 Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A ARTHRITIS RHEUM 2008 58 1 61-72
38. high primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr LEUKEMIA 2008 22 2 406-413 • Describes the correlation of inhibition of growth in myeloma cells by atacicept with TACI expression rate in subsets of myeloma patients.
39. 926820 Roche: Pharma pipeline. Roche Holding AG COMPANY WORLD WIDE WEB SITE 2008 April 17
40. 927622 TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Mackay F, Schneider P CYTOKINE GROWTH FACTOR REV 2008 19 3-4 263-276 •• Provides an updated review of the biology of TACI and highlights some questions about properties of TACI that remain unanswered.
41. 927982 APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B et al J EXP MED 1998 188 6 1185-1190
42. 927983 An APRIL to remember: Novel TNF ligands as therapeutic targets. Dillon SR, Gross JA, Ansell SM, Novak AJ NAT REV DRUG DISCOV 2006 5 3 235-246
43. 927990 BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D et al J EXP MED 1999 189 11 1747-1756
44. 928024 Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, Dimke D et al J BIOL CHEM 2000 275 45 35478-35485
45. 928069 Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G CELL 2002 108 3 383-394
46. 928070 TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B-cells and plasmablasts. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, Scott ML, Maquelin A, Belnoue E, Siegrist CA, Chevrier S et al BLOOD 2008 111 3 1004-1012
47. 928072 BAFF: A novel therapeutic target for autoimmunity. Kalled SL CURR OPIN INVESTIG DRUGS 2002 3 7 1005-1010
48. 928073 BAFF, APRIL and human B cell disorders. Tangye SG, Bryant VL, Cuss AK, Good KL SEMIN IMMUNOL 2006 18 5 305-317
49. 928074 B-cells move to centre stage: Novel opportunities for autoimmune disease treatment. Browning JL NAT REV DRUG DISCOV 2006 5 7 564-576
50. 928075 Raised serum APRIL levels in patients with systemic lupus erythematosus. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, Harada M, Horiuchi T ANN RHEUM DIS 2005 64 7 1065-1067
51. 928077 B-cell-targeted treatment for multiple sclerosis: Mechanism of action and clinical data. Hawker K CURR OPIN NEUROL 2008 21 Suppl 1 S19-S25
52. 928079 Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, Cachero TG, Finke D, Beermann F, Tschopp J J EXP MED 2001 194 11 1691-1697
53. 928083 BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K BLOOD 2004 103 8 3148-3157
54. 928086 Epidemiology of systemic lupus erythematosus. Petri M BEST PRACT RES CLIN RHEUMATOL 2002 16 5 847-858
55. 928088 Challenges in bringing the bench to bedside in drug development for SLE. Merrill JT, Erkan D, Buyon JP Nat REV DRUG DISCOV 2004 3 12 1036-1046
56. 928094 Genentech and Biogen Idec announce top-line results from phase II/III clinical study of rituxan in systemic lupus erythematosus. Genentech Inc PRESS RELEASE 2008 July 25
57. 940225 ZymoGenetics and Merck Serono restructure partnership. ZymoGenetics Inc PRESS RELEASE 2008 September 03
58. 943173 Information about lupus. Alliance for Lupus Research INTERNET SITE 2002 September 15
59. 943699 Engineering an APRIL-specific B-cell maturation antigen. Patel DR, Wallweber HJ, Yin J, Shriver SK, Marsters SA, Gordon NC, Starovasnik MA, Kelley RF J BIOL CHEM 2004 279 16 16727-16735
60. 944308 WO-02094852: TACI-immunoglobulin fusion protein. Rixon M, Gross JA WORLD PATENT 2002 November 28
61. 944309 WO-0040716: Soluble receptor BR43x2 and methods of using. Gross JA, Xu W, Madden K, Yee DP WORLD PATENT 2000 July 13
62. 944709 NCT00430495: A phase II dose-finding study of atacicept in rheumatoid arthritis (RA). CLINICALTRIALS.GOV 2008
63. 944710 NCT00664521: Atacicept in combination with rituximab in subjects with rheumatoid arthritis. CLINICALTRIALS.GOV 2008
64. 944711 NCT00595413: Study of atacicept in anti-TNFα-naive patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate. CLINICALTRIALS.GOV 2008
65. 944712 NCT00642902: Atacicept in multiple sclerosis, phase II. CLINICALTRIALS.GOV 2008
66. 944713 NCT00624468: Atacicept in optic neuritis, phase II. CLINICALTRIALS.GOV 2008
67. 944714 NCT00573157: The efficacy and safety of atacicept in combination with mycophenolate mofetil used to treat lupus nephritis. CLINICALTRIALS.GOV 2008
68. 944715 NCT00624338: Atacicept phase II/III in generalized systemic lupus erythematosus. CLINICALTRIALS.GOV 2008
69. 945057 APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Tschopp J et al J EXP MED 1998 188 6 1185-1190
70. 945058 BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer J, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Tschopp J et al J EXP MED 1999 189 11 1747-1756
71. 945280 Biologic therapies in rheumatology: Lessons learned, future directions. Strand V, Kimberly R, Isaacs JD NAT REV DRUG DISCOV 2007 6 1 75-92
72. 946934 Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam K-P, Noelle RJ J IMMUNOL 2008 180 5 3655-3659